[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588589":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":110,"collaborators":10,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":115,"sex":121,"minAge":122,"maxAge":10,"enrollmentInfo":123,"targetDuration":126,"studyType":127,"phases":10,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":86,"whyStopped":10,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"SCVF",null,"Probands with diagnosis of SCVF",[13,14],"Other: Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies","Genetic: DPP6 risk haplotype",{"label":16,"type":10,"description":17,"interventionNames":18},"IVF","Otherwise unexplained idiopathic ventricular fibrillation",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Control group","Unaffected healthy individuals matched for age, sex and ethnicity",[13],[24,28],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies","Semiquantitative measure of circulating anti-TREK-1 autoantibodies in plasma of study participants using a peptid microarray",[20,16,9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"GENETIC","DPP6 risk haplotype","Systematic genetic screening for the Dutch DPP6 risk haplotype in all study participants and correlation of results with the presence or absence of anti-TREK-1 autoantibodies",[16,9],[34],{"name":35,"affiliation":5,"role":36},"Christian Steinberg, MD","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Marina Sanchez, PhD","CONTACT","+14186568711","marina.sanchez@criucpq.ulaval.ca",{"name":44,"role":40,"phone":41,"phoneExt":10,"email":45},"Paule Banville, Study coordinator","paule.banville@criucpq.ulaval.ca",[47,63,73,84,100],{"facility":48,"status":49,"city":50,"state":51,"zip":10,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"St-Paul's Hospital - University of British Columbia","NOT_YET_RECRUITING","Vancouver","British Columbia","Canada","CA",{"type":55,"coordinates":56},"Point",[57,58],-123.11934,49.24966,{"lat":58,"lon":57},[61],{"name":62,"role":40,"phone":10,"phoneExt":10,"email":10},"Andrew D Krahn, MD",{"facility":64,"status":65,"city":66,"state":67,"zip":10,"country":52,"countryCode":53,"cosmosGeoPoint":68,"geoPoint":72,"contacts":10},"PHRI","ACTIVE_NOT_RECRUITING","Hamilton","Ontario",{"type":55,"coordinates":69},[70,71],-79.84963,43.25011,{"lat":71,"lon":70},{"facility":74,"status":49,"city":75,"state":67,"zip":10,"country":52,"countryCode":53,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Ottawa Heart Center","Ottawa",{"type":55,"coordinates":77},[78,79],-75.69812,45.41117,{"lat":79,"lon":78},[82],{"name":83,"role":40,"phone":10,"phoneExt":10,"email":10},"Simon Hansom, MD",{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":52,"countryCode":53,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Institut universitaire de cardiologie et pneumologie de Québec","RECRUITING","Québec","Quebec","G1V4G5",{"type":55,"coordinates":91},[92,93],-71.21454,46.81228,{"lat":93,"lon":92},[96],{"name":97,"role":40,"phone":98,"phoneExt":10,"email":99},"Steinberg Steinberg, MD","+4186568711","christian.steinberg@criucpq.ulaval.ca",{"facility":101,"status":65,"city":102,"state":10,"zip":10,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":10},"Amsterdam University Medical Center","Amsterdam","Netherlands","NL",{"type":55,"coordinates":106},[107,108],4.88969,52.37403,{"lat":108,"lon":107},{"type":36,"investigatorFullName":111,"investigatorTitle":112,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Christian Steinberg","MD","100588589","role-of-anti-trek-1-autoantibodies-in-scvf-100588589",false,"NCT06943365","Role of Anti-TREK-1 Autoantibodies in SCVF","Circulating Anti-TREK-1 Autoantibodies as Diagnostic and Prognostic Biomarkers in Short-Coupled Ventricular Fibrillation","TRACK-VF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of SCVF as per current criteria\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n\\- SCVF patients \\\u003C age 18","ALL","18 Years",{"count":124,"type":125},300,"ESTIMATED","24 Months","OBSERVATIONAL","Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.",[130,131],"Short-coupled Ventricular Fibrillation","Idiopathic Ventricular Fibrillation",[9,133,16],"anti-TREK-1 antibodies","2026-06-15",{"date":136,"type":137},"2026-06-16","ACTUAL",{"date":139,"type":137},"2025-05-01",{"date":141,"type":125},"2028-12-31",{"name":5,"class":6},5]